Innovation cure: Ipsen and the AI era
Ipsen is a global biopharmaceutical company with over 5,000 employees, focused on transformative medicines in oncology, rare diseases and neuroscience. With total sales of €3.0 billion in 2022, Ipsen markets medicines in over 100 countries.
Context
At Ipsen, the era of generative artificial intelligence is dawning. Faced with the need to innovate and stay at the cutting edge, Ipsen has embarked on an ambitious digital transformation project. The aim? To inspire and empower its employees to fully embrace the potential of AI.
Solution
Our collaboration with Ipsen was based on a structured and progressive approach. It began with an in-depth acculturation session, highlighting the fundamental principles of generative artificial intelligence. This laid the foundations for a series of six hands-on workshops, to effectively integrate tools such as Make and ChatGPT into Ipsen's processes.
This type of session, starting with acculturation and extending to more concrete application, paves the way for teams to become fully immersed in the AI and Nocode ecosystem. They are designed to develop technical skills tailored to the specific needs of their business use cases, fostering a deeper understanding and practical application of these innovative technologies.
.svg)
.svg)
